Metabolic complications and their mechanisms in patients with craniopharyngioma
(2025) In Best Practice and Research: Clinical Endocrinology and Metabolism- Abstract
After diagnosis of craniopharyngioma, patients frequently develop a rapid weight gain leading to morbid hypothalamic obesity due to disease- and/or treatment-associated hypothalamic lesions. Hypothalamic obesity should be diagnosed and treated in the context of hypothalamic syndrome. Hypothalamic syndrome includes neuroendocrine deficiencies, disruption of circadian rhythm, disturbed hunger-satiety and thirst feelings, temperature dysregulation, and neurocognitive, sleep and psychosocial behavioral problems. Long-term prognosis is frequently impaired by increased risk for metabolic syndrome, cardiovascular problems, severe impairments of health-related quality of life, and premature mortality. Treatment of hypothalamic syndrome is... (More)
After diagnosis of craniopharyngioma, patients frequently develop a rapid weight gain leading to morbid hypothalamic obesity due to disease- and/or treatment-associated hypothalamic lesions. Hypothalamic obesity should be diagnosed and treated in the context of hypothalamic syndrome. Hypothalamic syndrome includes neuroendocrine deficiencies, disruption of circadian rhythm, disturbed hunger-satiety and thirst feelings, temperature dysregulation, and neurocognitive, sleep and psychosocial behavioral problems. Long-term prognosis is frequently impaired by increased risk for metabolic syndrome, cardiovascular problems, severe impairments of health-related quality of life, and premature mortality. Treatment of hypothalamic syndrome is challenging. Recently, an algorithm for personalized, risk-specific treatment of hypothalamic syndrome has been published. Dextro-amphetamines and other central stimulating agents as well as glucagon-like peptide-1 receptor (GLP-1R) agonists may cause weight loss. Bariatric surgery is effective. However, non-reversible procedures are controversial due to ethical and legal considerations in minors. Hypothalamus-sparing treatment strategies and research on novel therapeutic agents for hypothalamic syndrome are warranted.
(Less)
- author
- Erfurth, Eva Marie LU and Müller, Hermann L.
- organization
- publishing date
- 2025
- type
- Contribution to journal
- publication status
- epub
- subject
- keywords
- craniopharyngioma, hypothalamus, metabolic syndrome, obesity, quality of life, sequelae
- in
- Best Practice and Research: Clinical Endocrinology and Metabolism
- article number
- 101999
- publisher
- Elsevier
- external identifiers
-
- scopus:105003374675
- pmid:40274451
- ISSN
- 1521-690X
- DOI
- 10.1016/j.beem.2025.101999
- language
- English
- LU publication?
- yes
- id
- d83f8f15-4901-41a3-8a20-96b7de6e1be6
- date added to LUP
- 2025-09-18 12:51:26
- date last changed
- 2025-10-16 16:44:07
@article{d83f8f15-4901-41a3-8a20-96b7de6e1be6,
abstract = {{<p>After diagnosis of craniopharyngioma, patients frequently develop a rapid weight gain leading to morbid hypothalamic obesity due to disease- and/or treatment-associated hypothalamic lesions. Hypothalamic obesity should be diagnosed and treated in the context of hypothalamic syndrome. Hypothalamic syndrome includes neuroendocrine deficiencies, disruption of circadian rhythm, disturbed hunger-satiety and thirst feelings, temperature dysregulation, and neurocognitive, sleep and psychosocial behavioral problems. Long-term prognosis is frequently impaired by increased risk for metabolic syndrome, cardiovascular problems, severe impairments of health-related quality of life, and premature mortality. Treatment of hypothalamic syndrome is challenging. Recently, an algorithm for personalized, risk-specific treatment of hypothalamic syndrome has been published. Dextro-amphetamines and other central stimulating agents as well as glucagon-like peptide-1 receptor (GLP-1R) agonists may cause weight loss. Bariatric surgery is effective. However, non-reversible procedures are controversial due to ethical and legal considerations in minors. Hypothalamus-sparing treatment strategies and research on novel therapeutic agents for hypothalamic syndrome are warranted.</p>}},
author = {{Erfurth, Eva Marie and Müller, Hermann L.}},
issn = {{1521-690X}},
keywords = {{craniopharyngioma; hypothalamus; metabolic syndrome; obesity; quality of life; sequelae}},
language = {{eng}},
publisher = {{Elsevier}},
series = {{Best Practice and Research: Clinical Endocrinology and Metabolism}},
title = {{Metabolic complications and their mechanisms in patients with craniopharyngioma}},
url = {{http://dx.doi.org/10.1016/j.beem.2025.101999}},
doi = {{10.1016/j.beem.2025.101999}},
year = {{2025}},
}